39 Results for "

ASGPr+

" in MedChemExpress (MCE) Product Catalog:
Products (39)

39 Results for "ASGPr+" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-P76736
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: Asgr2; Asgr-2; Asialoglycoprotein receptor 2; ASGP-R 2; ASGPR 2; Hepatic lectin 2; HL-2; mHL-2
Species:  
Source:  
1
1 Cited Publications
Cat. No.: HY-P7610
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: rHuASGR1, His; Asialoglycoprotein Receptor 1, ASGR1,
Species:  
Source:  
Cat. No.: HY-148476
CAS No.: 2999748-27-3
Purity:  98.05%
Target:  

LYTACs

Research Areas:  

Metabolic Disease

Tri-GalNAc-DBCO is a synthetic ligand composed of three GalNAc units connected to DBCO. Tri-GalNAc-DBCO can act as a ligand for the sialic acid-degrading protein receptor (ASGPR), and can be coupled with targeting proteins or small molecules to form GalNAc-LYTACs. Tri-GalNAc-DBCO specifically binds to ASGPR and, through receptor-mediated endocytosis, guides the coupled molecules to lysosomes for degradation .
Cat. No.: HY-148118A
CAS No.: 1159408-65-7
Purity:  98.09%
Target:  

LYTACs

Research Areas:  

Cancer

Tri-GalNAc(OAc)3 TFA is a trivalent N-acetylgalactosamine (GalNAc) derivative that can be used to synthesize GalNAc-LYTAC. Tri-GalNAc is a specific ligand targeting the asialoglycoprotein receptor (ASGPR), mediating the endocytosis and transport of cell surface proteins (such as EGFR, HER2) to lysosomes for degradation by lysosomal targeting chimeras (LYTACs). Tri-GalNAc significantly reduces the level of target proteins and inhibits downstream signaling pathways (such as EGFR-mediated Akt and MAPK signals). Tri-GalNAc(OAc)3 TFA can be used for hepatocyte targeting studies, and can degrade carcinogenic membrane proteins and inhibit tumor cell proliferation in liver cancer cell models .
Cat. No.: HY-139482
CAS No.: 1953146-81-0
Purity:  98.43%
Target:  

LYTACs

Research Areas:  

Cancer

tri-GalNAc-COOH is an asialoglycoprotein receptor (ASGPR) ligand that can be used for LYsosome TArgeting Chimera (LYTAC) research .
Cat. No.: HY-157950
CAS No.: 2936651-86-2
Target:  

Liposome

Research Areas:  

Cancer

DSPE-PEG2K-triGalNAc ammonium is a polar lipid composed of DSPE and tri-N-acetylgalactosamine that can be used to construct liposomes target to asialoglycoprotein receptor (ASGPR).
Cat. No.: HY-147354
CAS No.: 186613-57-0
Purity:  99.02%
Target:  

LYTACs

Research Areas:  

Cardiovascular Disease

TriGalNAc CBz is a GalNAc derivative and tri-GalNAc is an asialoglycoprotein receptor (ASGPR) ligand. TriGalNAc CBz can be used for mRNA drug delivery as well as lysosomal targeted chimerism (LYTAC) studies .
Cat. No.: HY-147012
CAS No.: 1159408-62-4
Purity:  ≥97.0%
Target:  

Drug Intermediate

Research Areas:  

Others

GalNAc-L96, a triantennary N-acetylgalactosamine (GalNAc), is a ligand of asialoglycoprotein receptor (ASGPR). GalNAc-L96 can be used to synthesize GalNAc-siRNA and can be used for oligonucleotide delivery .
Cat. No.: HY-173247
CAS No.: 2199491-27-3
GalNAc-NAG37 phosphoramidite is an N-acetylgalactosamine (GalNAc) derivative that acts as a ligand for the asialoglycoprotein receptor (ASGPR). GalNAc-NAG37 phosphoramidite can be used to synthesize GalNAc-siRNA and for oligonucleotide delivery .
Cat. No.: HY-147266
Purity:  95.83%
Synonyms: VIR-2218 sodium
Research Areas:  

Infection

Elebsiran (VIR-2218) sodium is a siRNA that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. Elebsiran sodium leads to a significant decrease in HBV surface antigen (HBsAg) and a reduction in viral load. Elebsiran sodium binds to the sialic acid-depleted glycoprotein receptor (ASGPR) on the surface of liver cells through the GalNAc ligand, achieving liver-targeted delivery and demonstrating improved liver safety. Elebsiran sodium can be used for the study of chronic HBV/HDV infections .
Cat. No.: HY-147102
CAS No.: 3062597-46-7
Purity:  99.40%
Target:  

LYTACs

Research Areas:  

Metabolic Disease

tri-GalNAc biotin is a biotinylated ASGPR (Asialoglycoprotein receptor) ligand. tri-GalNAc biotin promotes cellular uptake of neutravidin (NA) via ASGPR. tri-GalNAc biotin delivers neutravidin to lysosomes for degradation. tri-GalNAc biotin can be used for research of LYsosome TArgeting Chimera (LYTAC) .
Cat. No.: HY-150151A
Target:  

LYTACs

Research Areas:  

Cardiovascular Disease

GalNac-siRNA negative control (21nt) is the negative control form of GalNac-siRNA. GalNac-siRNA is an Asialoglycoprotein receptor (ASGPR)-targeted inhibitor conjugate. GalNac-siRNA is promising for research of hereditary transthyretin amyloidosis, acute hepatic porphyria, hemophilia and hypercholesterolemia .
Cat. No.: HY-156994
CAS No.: 1426160-58-8
Research Areas:  

Others

ASGPR ligand-1 (Compound int-CC2) is an asialoglycoprotein receptor (ASGPR) ligand with a binding Kd value of 0.9 nM. ASGPR ligand-1 is applicable to research on lysosome degradation-related diseases .
Cat. No.: HY-171910
CAS No.: 3099288-71-5
Research Areas:  

Others

tri(GalNAc-PEG2)-PEG4-cyclo(Ac-DCAW-{Arg(3F-Ph)-PEG2}-LGELVWCT) (Cys2-Cys12) is an asialoglycoprotein receptor (ASGPR) ligand that can be used for LYsosome TArgeting Chimera (LYTAC) research .
Cat. No.: HY-153184
CAS No.: 1159408-61-3
GalNAc-L96 free base is a conjugate of GalNAc and its ligand L96. When conjugated with the A-rich HCV sequence (H12), GalNAc-L96 free base binds potently to ASGPR, with a Ki value of 10.4 nM. GalNAc-L96 free base promotes siRNA delivery to hepatocytes .
Cat. No.: HY-179737
CAS No.: 3062599-51-0
Target:  

LYTACs

Research Areas:  

Metabolic Disease

ASGPR ligand-2 (Compound 366) is an asialoglycoprotein receptor (ASGPR) binder. ASGPR ligand-2 can be coupled with recognition elements of target proteins (such as antibodies or antigen-binding fragments), and through the endocytosis mediated by ASGPR, the target protein is delivered to the lysosomes of liver cells, promoting the degradation of the target protein. ASGPR ligand-2 can be used for the research of metabolic disease .
Cat. No.: HY-147266A
CAS No.: 2648009-64-5
Synonyms: VIR-2218
Research Areas:  

Infection

Elebsiran (VIR-2218) is a siRNA that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. Elebsiran leads to a significant decrease in HBV surface antigen (HBsAg) and a reduction in viral load. Elebsiran binds to the sialic acid-depleted glycoprotein receptor (ASGPR) on the surface of liver cells through the GalNAc ligand, achieving liver-targeted delivery and demonstrating improved liver safety. Elebsiran can be used for the study of chronic HBV/HDV infections .
Cat. No.: HY-142881
CAS No.: 2378837-67-1
Target:  

LYTACs

Research Areas:  

Others

D-MoDE-A (1) is a bifunctional small molecule that mediates the degradation of extracellular proteins through the asialoglycoprotein receptor (ASGPR).
Cat. No.: HY-153527
CAS No.: 1159408-72-6
Target:  

LYTACs

Research Areas:  

Metabolic Disease

GalNAc-L96 analog is an intermediate in the synthesis of the asialoglycoprotein receptor (ASGPR) ligand GalNAc-L96 (HY-147012).
Cat. No.: HY-145649A
CAS No.: 2380166-34-5
Synonyms: AD-85481 sodium; ALN-AGT sodium
Zilebesiran (AD-85481; ALN-AGT) sodium is a long-acting liver-targeted small interfering RNA (siRNA) antihypertensive agent. Zilebesiran sodium binds to the hepatic asialoglycoprotein receptor (ASGPR), activates the RNA-induced silencing complex to degrade hepatic angiotensinogen mRNA, thereby inhibiting the gene expression and synthesis of angiotensinogen. Zilebesiran sodium dose-dependently reduces serum angiotensinogen levels and 24-hour ambulatory blood pressure, with its effect persisting throughout the circadian cycle. Zilebesiran sodium is applicable to research related to hypertension .